|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after ...
On June 24, 2016, Pfizer (PFE) announced that it had completed the acquisition of Anacor Pharmaceuticals for a total net value of $5.2 billion. The acquisition added crisaborole.
On June 24, Pfizer acquired Anacor Pharmaceuticals for a total enterprise value of ~$5.2 billion. Pfizer seemed to be interested in Anacor’s two major assets.